𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease

✍ Scribed by Lonneke M.L. de Lau; Dagmar Verbaan; Johan Marinus; Peter Heutink; Jacobus J. van Hilten


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
1006 KB
Volume
27
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background:

The A‐allele of the catechol‐O‐methyltransferase (COMT) Val158Met polymorphism is associated with decreased enzymatic activity and higher dopamine availability.

Methods:

We studied 219 patients with PD who were free of dyskinesias at baseline and underwent thorough annual examinations.

Results:

The A‐allele of the COMT Val158Met polymorphism was related to an increased risk of developing dyskinesias during follow‐up, in a dose‐dependent manner (adjusted hazard ratios for the AG and AA genotypes [compared to GG]: 2.09 [95% confidence interval (CI), 1.07–4.06] and 2.81 [CI, 1.43–5.54], respectively).

Conclusions:

This finding suggests that genetic factors may affect susceptibility to dyskinesias in PD. © 2011 Movement Disorder Society


📜 SIMILAR VOLUMES


Catechol-O-methyltransferase val158met a
✍ Jeroen Hoogland; Rob M.A. de Bie; Caroline H. Williams-Gray; Dino Muslimović; Be 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Cognitive dysfunction is one of the most incapacitating non‐motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol‐O‐methyltransferase (COMT), an enzyme that degrades dopamine.

Influence of the tyrosine hydroxylase va
✍ Keizo Yoshida; Hisashi Higuchi; Hitoshi Takahashi; Mitsuhiro Kamata; Kazuhiro Sa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## Objective Genetic polymorphisms of the noradrenergic pathway can be factors to predict the effect of antidepressants when their pharmacological mechanisms of action include the noradrenergic system. The purpose of the present study was to determine whether the tyrosine hydroxylase (

Catechol-O-methyltransferase inhibitors:
✍ Jasper Dingemanse 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 2 views

Substitution therapy with levodopa and a peripheral inhibitor of aromatic L-amino acid decarboxylase (AADC) is the cornerstone in the treatment of Parkinson's disease. Chronic therapy with levodopa, however, is associated with the occurrence of motor complications that are partially related to the p

G/A1947 polymorphism in catechol-O-methy
✍ T. Xie; Dr. S. L. Ho; L. S. W. Li; O. C. K. Ma 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB

## Abstract High and low catechol‐__O__‐methyltransferase (COMT) activity is significantly determined by thermostability, which is caused by a valine/methionine~108~ polymorphism associated with polymorphic G/A~1947~ bases, in exon 4 of the COMT gene. Our allelic association study on this polymorph

Genetic polymorphism of catechol-O-methy
✍ Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract We explored the potential effect of catechol‐__O__‐methyltransferase (COMT) genetic polymorphism on the pharmacokinetics and pharmacodynamics of a standard oral dose of levodopa in patients with Parkinson's disease (PD). We prospectively collected blood samples for COMT genotyping from